Product image of Mibi Technescan (Copper Tetramibi Tetrafluoroborate) supplied by GNH India

Mibi Technescan

Active Ingredient:
Copper Tetramibi Tetrafluoroborate
Origin:
EU

Mibi Technescan (Copper Tetramibi Tetrafluoroborate)

Copper Tetramibi Tetrafluoroborate, the active ingredient in Mibi Technescan, is a drug presented as an intravenous formulation for clinical use. Its therapeutic role and target patient population have not been publicly disclosed.
GNH India supplies Mibi Technescan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Curium Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mibi Technescan is an investigational compound with limited publicly disclosed therapeutic applications.

  • Investigational oncology: evaluated in early‑phase clinical studies for potential antitumor activity.
  • Transplant medicine: explored as an adjunct in experimental protocols for graft tolerance.
  • Rare metabolic disorders: studied in pre‑clinical models for enzyme modulation.

How It Works

  • The precise mechanism of action of Copper Tetramibi Tetrafluoroborate has not been publicly detailed. Available information suggests it may interact with cellular copper‑dependent pathways, potentially influencing enzymatic activity or oxidative processes, but definitive pharmacological targets remain unconfirmed.

Side Effects

Adverse reaction data for Mibi Technescan are limited. Reported observations are based on early clinical observations and pre‑clinical studies.

Common Side Effects

  • Mild infusion site irritation: transient redness or discomfort at the injection site.
  • Transient headache: occasional mild headache during or after infusion.
  • Nausea: occasional mild nausea reported.

Serious or Rare Side Effects

  • Hypersensitivity reaction: rare cases of rash, pruritus, or anaphylaxis.
  • Hepatic enzyme elevation: occasional increase in liver function tests.
  • Renal function alteration: rare reports of transient creatinine rise.
  • Hematologic changes: occasional mild thrombocytopenia.
  • Cardiac arrhythmia: isolated reports of rhythm disturbances.

Precautions & Warnings

When handling Mibi Technescan, consider the following precautions:

  • Patient assessment: evaluate baseline organ function before administration.
  • Infusion monitoring: observe for signs of hypersensitivity during infusion.
  • Drug interactions: review concomitant medications for potential additive toxicity.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
  • Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential drug interactions for Mibi Technescan are not fully characterized. Known considerations include:

Major Interactions (Avoid)

  • Strong CYP450 inhibitors: may increase systemic exposure if metabolic pathways are involved.
  • Immunosuppressants: concurrent use could amplify immunomodulatory effects.

Moderate Interactions (Monitor Closely)

  • Nephrotoxic agents: monitor renal function when combined.
  • Hepatotoxic drugs: assess liver enzymes regularly.
  • Anticoagulants: observe coagulation parameters for additive bleeding risk.

Frequently Asked Questions

Mibi Technescan is an investigational intravenous drug containing Copper Tetramibi Tetrafluoroborate. It is currently being evaluated in clinical studies for potential use in oncology, transplant medicine, and certain rare metabolic disorders, but no approved therapeutic indication has been established.

The exact pharmacological mechanism of Copper Tetramibi Tetrafluoroborate is not publicly disclosed. Preliminary data suggest it may modulate copper‑dependent cellular pathways, influencing enzyme activity or oxidative stress, but definitive targets have not been confirmed.

Dosing of Mibi Technescan is determined by the prescribing clinician based on the specific study protocol, patient characteristics, and therapeutic intent. No standardized dose is publicly available.

Safety data for Mibi Technescan in pregnancy or lactation are insufficient. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Mibi Technescan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mibi Technescan shares a copper‑based core with other experimental agents, but differences may exist in molecular structure, formulation, and pharmacokinetic profile. Direct comparisons are limited to pre‑clinical data, and definitive efficacy or safety advantages have not been established.

Mibi Technescan should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in its original packaging to maintain stability and integrity until use.

Mibi Technescan is administered intravenously by a qualified healthcare professional. The infusion rate and duration are defined by the clinical protocol or prescribing information and should be monitored for adverse reactions.

Serious risks reported in early studies include hypersensitivity reactions such as rash or anaphylaxis, hepatic enzyme elevations, renal function changes, hematologic abnormalities, and rare cardiac arrhythmias. Patients should be monitored closely for these events during and after infusion.

Mibi Technescan should not be used in patients with known hypersensitivity to the product or its components, in individuals with uncontrolled severe hepatic or renal impairment, and in pregnant or breastfeeding women unless the potential benefit outweighs the risk as judged by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Copper Tetramibi Tetrafluoroborate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT